{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:42:31Z","timestamp":1790404951747,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100012729","name":"Clinical and Translational Science Collaborative of Cleveland, School of Medicine, Case Western Reserve University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012729","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"DOI":"10.1038\/s41523-025-00844-6","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T13:51:48Z","timestamp":1764078708000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Racial and demographic disparities in glp-1ra use among breast cancer patients with Type 2 Diabetes"],"prefix":"10.1038","volume":"11","author":[{"given":"Jasmin","family":"Hundal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer S.","family":"Ashruf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Basen-Engquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Kaelber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine S.","family":"Sukumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"844_CR1","doi-asserted-by":"publisher","first-page":"e249548","DOI":"10.1001\/jamanetworkopen.2024.9548","volume":"7","author":"BB Bekele","year":"2024","unstructured":"Bekele, B. B. et al. Preexisting diabetes and breast cancer treatment among low-income women. JAMA Netw. Open 7, e249548 (2024).","journal-title":"JAMA Netw. Open"},{"key":"844_CR2","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"844_CR3","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1097\/SLA.0000000000005375","volume":"275","author":"N Goel","year":"2022","unstructured":"Goel, N. et al. Structural racism and breast cancer-specific survival: impact of economic and racial residential segregation. Ann. Surg. 275, 776\u2013783 (2022).","journal-title":"Ann. Surg."},{"key":"844_CR4","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1158\/0008-5472.CAN-24-1359","volume":"84","author":"M Falcone","year":"2024","unstructured":"Falcone, M. et al. Impact of structural racism and social determinants of health on disparities in breast cancer mortality. Cancer Res 84, 3924\u20133935 (2024).","journal-title":"Cancer Res"},{"key":"844_CR5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/cncr.33889","volume":"128","author":"AE Connor","year":"2022","unstructured":"Connor, A. E., Kaur, M., Sheng, J. Y. & Hayes, J. H. Racial disparities in mortality outcomes among women diagnosed with breast cancer in Maryland: Impact of cardiovascular disease and clinical characteristics. Cancer 128, 727\u2013736 (2022).","journal-title":"Cancer"},{"key":"844_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2020.105998","volume":"92","author":"RA Shelby","year":"2020","unstructured":"Shelby, R. A. et al. Improving health engagement and lifestyle management for breast cancer survivors with diabetes. Contemp. Clin. Trials 92, 105998 (2020).","journal-title":"Contemp. Clin. Trials"},{"key":"844_CR7","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2337\/dc17-2012","volume":"41","author":"IC Lega","year":"2018","unstructured":"Lega, I. C. et al. The impact of diabetes on breast cancer treatments and outcomes: a population-based study. Diabetes Care 41, 755\u2013761 (2018).","journal-title":"Diabetes Care"},{"key":"844_CR8","doi-asserted-by":"publisher","first-page":"e249548","DOI":"10.1001\/jamanetworkopen.2024.9548","volume":"7","author":"BB Bekele","year":"2024","unstructured":"Bekele, B. B. et al. Preexisting Diabetes and Breast Cancer Treatment Among Low-Income Women. JAMA Netw. Open 7, e249548 (2024).","journal-title":"JAMA Netw. Open"},{"key":"844_CR9","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1002\/cncr.33290","volume":"127","author":"CE Taylor","year":"2021","unstructured":"Taylor, C. E. & Meisel, J. L. Weighing the influence of race and obesity on outcomes in patients with early-stage breast cancer. Cancer 127, 834\u2013836 (2021).","journal-title":"Cancer"},{"key":"844_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0787-1","volume":"21","author":"K Lee","year":"2019","unstructured":"Lee, K., Kruper, L., Dieli-Conwright, C. M. & Mortimer, J. E. The Impact of Obesity on Breast Cancer Diagnosis and Treatment. Curr. Oncol. Rep. 21, 41 (2019).","journal-title":"Curr. Oncol. Rep."},{"key":"844_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2901","volume":"13","author":"JL Patnaik","year":"2011","unstructured":"Patnaik, J. L., Byers, T., DiGuiseppi, C., Dabelea, D. & Denberg, T. D. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 13, R64 (2011).","journal-title":"Breast Cancer Res."},{"key":"844_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/jnci\/djaa096","volume":"113","author":"C Ramin","year":"2021","unstructured":"Ramin, C. et al. All-cause and cardiovascular disease mortality among breast cancer survivors in CLUE II, a long-standing community-based cohort. J. Natl. Cancer Inst. 113, 137\u2013145 (2021).","journal-title":"J. Natl. Cancer Inst."},{"key":"844_CR13","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies, M. et al. Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 397, 971\u2013984 (2021).","journal-title":"Lancet"},{"key":"844_CR14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311\u2013322 (2016).","journal-title":"N. Engl. J. Med."},{"key":"844_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2337\/dc08-1355","volume":"32","author":"M Nauck","year":"2009","unstructured":"Nauck, M. et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes. Diabetes Care 32, 84\u201390 (2009).","journal-title":"Diabetes Care"},{"key":"844_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","volume":"6","author":"RE Pratley","year":"2018","unstructured":"Pratley, R. E. et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 6, 275\u2013286 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"844_CR17","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834\u20131844 (2016).","journal-title":"N. Engl. J. Med."},{"key":"844_CR18","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221\u20132232 (2023).","journal-title":"N. Engl. J. Med."},{"key":"844_CR19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer, M. et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 392, 427\u2013437 (2025).","journal-title":"N. Engl. J. Med."},{"key":"844_CR20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2174\/1573399813666170414101450","volume":"14","author":"SC Peterson","year":"2018","unstructured":"Peterson, S. C. & Barry, A. R. Effect of glucagon-like peptide-1 receptor agonists on all-cause mortality and cardiovascular outcomes: a meta-analysis. CDR 14, 273\u2013279 (2018).","journal-title":"CDR"},{"key":"844_CR21","doi-asserted-by":"publisher","first-page":"e214182","DOI":"10.1001\/jamahealthforum.2021.4182","volume":"2","author":"LA Eberly","year":"2021","unstructured":"Eberly, L. A. et al. Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US. JAMA Health Forum 2, e214182 (2021).","journal-title":"JAMA Health Forum"},{"key":"844_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2337\/dc22-0383","volume":"46","author":"SJ Cromer","year":"2023","unstructured":"Cromer, S. J., Lauffenburger, J. C., Levin, R. & Patorno, E. Deficits and disparities in early uptake of glucagon-like peptide 1 receptor agonists and SGLT2i among medicare-insured adults following a new diagnosis of cardiovascular disease or heart failure. Diabetes Care 46, 65\u201374 (2023).","journal-title":"Diabetes Care"},{"key":"844_CR23","doi-asserted-by":"publisher","DOI":"10.2337\/db25-1163-P","volume":"74","author":"PY Chu","year":"2025","unstructured":"Chu, P. Y., Kelly, A., Vajravelu, M. E., Hennessy, S. & Amaral, S. 1163-P: Disparities in glucagon-like peptide 1 receptor agonist (GLP-1RA) utilization in pediatric type 2 diabetes (T2D). Diabetes 74, 1163-P (2025).","journal-title":"Diabetes"},{"key":"844_CR24","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1001\/jama.2022.13885","volume":"328","author":"JA Lamprea-Montealegre","year":"2022","unstructured":"Lamprea-Montealegre, J. A. et al. Association of race and ethnicity with prescription of SGLT2 inhibitors and GLP1 receptor agonists among patients with type 2 diabetes in the veterans health administration system. JAMA 328, 861 (2022).","journal-title":"JAMA"},{"key":"844_CR25","doi-asserted-by":"crossref","unstructured":"Kukhareva, P. V. et al. Racial and Ethnic Disparities in Prescribing of GLP-1 Receptor Agonists in the United States: A Retrospective Cohort Analysis [Internet]. [cited 2025 Aug 3]. Available from: http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2024.10.28.24316312 (2024).","DOI":"10.1101\/2024.10.28.24316312"},{"key":"844_CR26","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1001\/jamaoncol.2021.1499","volume":"7","author":"EV Bandera","year":"2021","unstructured":"Bandera, E. V. et al. Association of body mass index, central obesity, and body composition with mortality among black breast cancer survivors. JAMA Oncol. 7, 1186 (2021).","journal-title":"JAMA Oncol."},{"key":"844_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115489","volume":"223","author":"C Dauccia","year":"2025","unstructured":"Dauccia, C. et al. Body mass index and weight changes in patients with HER2-positive early breast cancer: a sub-analysis of the APHINITY trial. Eur. J. Cancer 223, 115489 (2025).","journal-title":"Eur. J. Cancer"},{"key":"844_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00754-7","volume":"11","author":"S Yaacobi Peretz","year":"2025","unstructured":"Yaacobi Peretz, S. et al. Body composition metrics as a determinant of trastuzumab deruxtecan related toxicity and response. npj Breast Cancer 11, 38 (2025).","journal-title":"npj Breast Cancer"},{"key":"844_CR29","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae116","volume":"8","author":"L Nair","year":"2024","unstructured":"Nair, L., Asuzu, P. & Dagogo-Jack, S. Ethnic disparities in the risk factors, morbidity, and mortality of cardiovascular disease in people with diabetes. J. Endocr. Soc. 8, bvae116 (2024).","journal-title":"J. Endocr. Soc."},{"key":"844_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1258348","volume":"12","author":"MY Yu","year":"2024","unstructured":"Yu, M. Y., Velasquez, A. J., Campos, B. & Robinette, J. W. Perceived neighborhood disorder and type 2 diabetes disparities in Hispanic, Black, and White Americans. Front Public Health 12, 1258348 (2024).","journal-title":"Front Public Health"},{"key":"844_CR31","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028409","volume":"12","author":"Z Raisi-Estabragh","year":"2023","unstructured":"Raisi-Estabragh, Z. et al. Racial disparities in obesity-related cardiovascular mortality in the United States: temporal trends from 1999 to 2020. JAHA 12, e028409 (2023).","journal-title":"JAHA"},{"key":"844_CR32","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1002\/cncr.34173","volume":"128","author":"TJ Ballinger","year":"2022","unstructured":"Ballinger, T. J. et al. Impact of African ancestry on the relationship between body mass index and survival in an early-stage breast cancer trial (ECOG-ACRIN E5103). Cancer 128, 2174\u20132181 (2022).","journal-title":"Cancer"},{"key":"844_CR33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10549-011-1705-x","volume":"131","author":"MF Abdel-Maksoud","year":"2012","unstructured":"Abdel-Maksoud, M. F. et al. Behavioral risk factors and their relationship to tumor characteristics in Hispanic and non-Hispanic white long-term breast cancer survivors. Breast Cancer Res. Treat. 131, 169\u2013176 (2012).","journal-title":"Breast Cancer Res. Treat."},{"key":"844_CR34","doi-asserted-by":"publisher","first-page":"e2035792","DOI":"10.1001\/jamanetworkopen.2020.35792","volume":"4","author":"RG McCoy","year":"2021","unstructured":"McCoy, R. G. et al. Comparison of diabetes medications used by adults with commercial insurance vs medicare advantage, 2016 to 2019. JAMA Netw. Open 4, e2035792 (2021).","journal-title":"JAMA Netw. Open"},{"key":"844_CR35","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.2337\/dc24-2746","volume":"48","author":"D Zhang","year":"2025","unstructured":"Zhang, D. et al. Association of patient cost sharing with adherence to GLP-1RA and adverse health outcomes. Diabetes Care 48, 1329\u20131336 (2025).","journal-title":"Diabetes Care"},{"key":"844_CR36","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1111\/jgs.15790","volume":"67","author":"SJ Pilla","year":"2019","unstructured":"Pilla, S. J., Segal, J. B., Alexander, G. C., Boyd, C. M. & Maruthur, N. M. Differences in national diabetes treatment patterns and trends between older and younger adults. J. Am. Geriatr. Soc. 67, 1066\u20131073 (2019).","journal-title":"J. Am. Geriatr. Soc."},{"key":"844_CR37","doi-asserted-by":"crossref","unstructured":"Gratzl, S. et al. Monitoring Report: GLP-1 RA Prescribing Trends \u2013 June Data [Internet]. 2025 [cited 2025 Aug 13]. Available from: http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.03.06.25323524 (2025).","DOI":"10.1101\/2025.03.06.25323524"}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00844-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00844-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00844-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T13:51:50Z","timestamp":1764078710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00844-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["844"],"URL":"https:\/\/doi.org\/10.1038\/s41523-025-00844-6","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"16 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"131"}}